Article
Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Anticancer research - 1 Aug 2021
Sato Taro, Osumi Hiroki, Shinozaki Eiji, Ooki Akira, Shimozaki Keitaro, Kamiimabeppu Daisaku, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Takahari Daisuke, Chin Keisho, Yamaguchi Kensei
Abstract excerpt
BACKGROUND/AIM: Primary tumor location and RAS and BRAF V600E mutations are predictors of the efficacy of epidermal growth factor receptor (EGFR) inhibitors. However, there are limited reports on their effects on the outcomes of third-line chemotherapy with EGFR inhibitors in metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS: We retrospectively collected the clinical data of KRAS exon 2 wild type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.